Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol

BACKGROUND: Hodgkin’s lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) are the two most common tumors expressing CD30. Internationally, a clinical study that is being conducted involving adults with recurrent or refractory HL or ALCL suggests efficacy of brentuximab vedotin (SGN-35). Pediatri...

Descripción completa

Detalles Bibliográficos
Autores principales: Sekimizu, Masahiro, Iguchi, Akihiro, Mori, Tetsuya, Koga, Yuhki, Kada, Akiko, Saito, Akiko M., Horibe, Keizo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796474/
https://www.ncbi.nlm.nih.gov/pubmed/29390984
http://dx.doi.org/10.1186/s12885-018-4042-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796474/
https://www.ncbi.nlm.nih.gov/pubmed/29390984
http://dx.doi.org/10.1186/s12885-018-4042-1

Ejemplares similares